Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
GlobalData on MSN5d
Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPFTrevi Therapeutics has finished enrolling subjects in a trial of investigational Haduvio for treating chronic cough in IPF ...
Trevi Therapeutics (TRVI)has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with ...
Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release ...
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary ...
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary ...
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback